VENETOKLAKS+ AZASİTİDİN PROTOKOLÜ

Kaynaklar:

1- DiNardo et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised,open-label, phase 1b study Di Nardo et al. Lancet Oncol 19: 216-228 

2- DiNardo et al. (2019) Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukaemia. Blood. 133(1):7-17

3- DiNardo CD, Jonas BA, Pullarkat V, et al. . Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. 

4- DiNardo CD, Pratz K, Pullarkat V, et al. . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.

5- DiNardo CD, Pratz KW, Letai A, et al. . Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216-228.

6- Pollyea DA, Pratz K, Letai A, et al. . Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208-217. 

7-Michaelis LC. Venetoclax in AML: aiming for “just right”. Blood. 2019;133(1):3-4. 

8- Pollyea DA. The case for abandoning induction chemotherapy. The Hematologist. 2017;14(3):1. 

9-Pollyea DA. Acute myeloid leukemia drug development in the post-venetoclax era. Am J Hematol. 2019;94(9):959-962.

10-Pei S, Pollyea DA, Gustafson A, et al. . Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536-551. 

11- Döhner H, Estey E, Grimwade D, et al. . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447